



Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRS	T NAMED INVENTOR		ATTORNEY DOCKET NO.
09/544,517	04/06/00	LUCHE	ı	R	200125.410
			EXAMINER		
000500 HM22/0821 SEED INTELLECTUAL PROPERTY LAW GROUP PLL 701 FIFTH AVE				PATTER ART UNIT	SON.C PAPER NUMBER
SUITE 6300 SEATTLE WA				1652 DATE MAILED:	08/21/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

		Application No.	Applicant(s)
		09/544,517	LUCHE ET AL.
Office Action Summary		Examiner	Art Unit
		Charles L. Patterson, Jr.	1652
Period fo	The MAILING DATE of this communication ap r Reply	pears on the cover sheet with the	correspondence address
THE N - Exten after : - If the - If NO - Failur - Any n	ORTENED STATUTORY PERIOD FOR REPL MAILING DATE OF THIS COMMUNICATION. Issions of time may be available under the provisions of 37 CFR 1. SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a rep- period for reply is specified above, the maximum statutory period re to reply within the set or extended period for reply will, by statut eply received by the Office later than three months after the mailing ad patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a reply be to be to be within the statutory minimum of thirty (30) do will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDON	imely filed ays will be considered timely. m the mailing date of this communication. ED (35 U.S.C. § 133).
1)	Responsive to communication(s) filed on	·	
2a)□	This action is FINAL . 2b) T	his action is non-final.	
3) 🗌	Since this application is in condition for allow closed in accordance with the practice unde	vance except for formal matters, r <i>Ex parte Quayle</i> , 1935 C.D. 11,	prosecution as to the merits is 453 O.G. 213.
Dispositi	ion of Claims		
4)🛛	Claim(s) 1-49 is/are pending in the application	on.	
	4a) Of the above claim(s) is/are withdra	awn from consideration.	
5)	Claim(s) is/are allowed.		
6)	Claim(s) is/are rejected.		
7)	Claim(s) is/are objected to.		
8)⊠	Claim(s) 1-49 are subject to restriction and/o	r election requirement.	
Applicat	ion Papers		
9)[The specification is objected to by the Examir	ner.	
10)	The drawing(s) filed on is/are: a) acc		
	Applicant may not request that any objection to	the drawing(s) be held in abeyance.	See 37 CFR 1.85(a).
11)	The proposed drawing correction filed on		proved by the Examiner.
	If approved, corrected drawings are required in		
12)	The oath or declaration is objected to by the B	Examiner.	
_	under 35 U.S.C. §§ 119 and 120		
13)	Acknowledgment is made of a claim for fore	ign priority under 35 U.S.C. § 119	9(a)-(d) or (f).
a)) All b) Some * c) None of:		
	1. Certified copies of the priority docume		
	2. Certified copies of the priority docume		
*	3. Copies of the certified copies of the properties of the propert	Bureau (PCT Rule 17.2(a)).	
	Acknowledgment is made of a claim for dome		
	a) The translation of the foreign language Acknowledgment is made of a claim for dome	provisional application has been	received.
Attachme		, ,	
1) Not	ice of References Cited (PTO-892) ice of Draftsperson's Patent Drawing Review (PTO-948) ormation Disclosure Statement(s) (PTO-1449) Paper No(s	5) Notice of Inform	nary (PTO-413) Paper No(s) nal Patent Application (PTO-152)
LI C Potent and	Trademark Office		_

Page 2 Application/Control Number: 09/544,517 Art Unit: 1652 Restriction to one of the following inventions is required under 35 U.S.C. 121: Claims 1, 26-29 and 47-49, drawn to a DSP-4 polypeptide, a method I. for screening for an agent that modulates DSP-4 activity and a method of screening a molecule for the ability to interact with DSP-4, classified in class 435, subclass 21 and 196. Claims 2-14 and 22-25, drawn to a polynucleotide, a vector con-II. taining the polynucleotide, a host cell containing the vector, an antisense polynucleotide, a method of producing DSP-4 by using the host cell and a method of detecting DSP-4 expression, classified in class 435, subclasses 196, 320.1, 252.3 and class 536, subclass 23.2 and 24.3. III. Claims 15-21, drawn to an antibody, a pharmaceutical composition comprising the antibody, a method of use of the antibody, classified in class 435, subclass 7.4 and class 530, subclass 387.9. Claims 30-32 and 42, drawn to a method for screening for a agent IV. that modulates DSP-4 activity, classified in class 435, subclass 6. Claims 33 and 36-39, drawn to a method for modulating a proliferv. ative response in a cell, classified in classes 424 and 514, numerous subclasses. Claims 34 and 36-39, drawn to a method for modulating different:-VI. ation of a cell, classified in classes 424 and 514, numerous subclasses. VII. Claims 35-41, drawn to a method for modulating survival of a cell, classified in classes 424 and 514, numerous subclasses.

Page 3 Application/Control Number: 09/544,517 Art Unit: 1652 VIII. Claims 43-44, drawn to a method for treating a patient afflicted with a disorder associated with DSP-4 activity, classified in class 424 and 514, numerous subclasses. Claims 45-46, drawn to a DSP-4 substrate trapping mutant polypep-IX. tide, classified in class 530, subclass 350. Note that Groups V-VII contain claims 36-39. The inventions are distinct, each from the other because: Groups I-III and IX are drawn to completely different chemical compounds that patentably distinct. The method of Group IV involves a DSP-4 promoter and is unrelated to any of the other groups. Groups V-VII involve contacting a cell with an unspecified agent that modulates DSP-4 activity and are unrelated to any of the other groups. Group VIII involves administering to a patient an unspecified agent that modulates DSP-4 activity and is unrelated to any other of the groups. Group IX a drawn to a DSP-4 substrate trapping mutant protein that has a reduced activity, including no activity. The instant protein is chemically different from the polypeptide of Group I and is patentably distinct. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and recognized divergent subject matter, restriction for examination purposes as indicated is proper. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Page 4 Application/Control Number: 09/544,517 Art Unit: 1652 Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charles L. Patterson, Jr., PhD, whose telephone number is 703-308-1834. The examiner can normally be reached on Monday - Friday, 7:30-4:00. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy can be reached on 703-308-3804. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-7401 for regular communications and 703-308-0294 for After Final communications. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196. Patterson, Jr. Primary Examiner Art Unit 1652 Patterson August 21, 2001